29th-31st January 2018

Paris, France

Day One
Wednesday 25th January, 2017

Day Two
Thursday 26th January, 2017

Registration & Networking

Chair’s Opening Remarks

Seizing the Microbiome: Can We Sort the Hype from the Hope?

Perspectives on a Microbiome-Based Industry: How Far Are We From Science to Products?


  • What are the most successful microbiome trends with clear therapeutic potential?
  • Exploring the current financial perspective in an emerging microbiome based industry
  • Why the microbiome industry is set to be bigger than the biotechnology bubble

Studying Microbiome-Host Interactions to Translate Microbiome Drugs into the Clinic

  • David Cook Executive Vice President of Research & Development and, Chief Scientific Officer Seres Therapeutics


  • Review of approaches to mine microbiological and functional information from human
  • clinical trials
  • Using mechanistic data and pharmacological models to design and test microbiome drugs
  • Discussion of regulatory and CMC considerations for translating microbiome drugs into clinical trials

EB8010 – A Novel Therapeutic Approach Targeting the Microbiome in Patients With Crohn’s Disease.


  • Emerging evidence suggests that the microbiome plays an important role in triggering an abnormal mucosal immune response in patients with Crohn’s Disease.
  • Independent studies have demonstrated an imbalance of the microbiome with a significant
  • increase of E. coli with invasive properties, termed adherent-invasive E. coli (AIEC). These
  • AIEC bacteria attach to the gut wall of susceptible patients via the fimbrial adhesion protein
  • FimH, and subsequently trigger inflammation by invading and proliferating within the gut wall.
  • EB8018 is a novel first-in-class molecule targeted to disarm AIEC bacteria by blocking the FimH adhesion and reducing the subsequent production of inflammatory cytokines in the gut wall.

Microbial Adaptations of the Microbiome


  • Delivering concepts and tools that target microbial integration in the microbiome
  • Understanding how persistence probabilities in the microbiome can be learned from longitudinal studies
  • Using metatranscriptomics to show microbiome response to new microorganisms

Morning Refreshments and Speed Networking

Translating the Microbiome: Moving From Observational Science to Evidence-Based Medicine

Where the Microbiome Will Matter for the Pharmaceutical Industry and Why


  • Positioning in academics and a microbiome start-up, in the largest medical centre in the world, provides a unique perspective on translational microbiome research
  • Clear evolution of project design: from retrospective to prospective, from associations to causality
  • Critical mass is building for the phase of pharma-based microbiome initiatives

Human-Microbe Interactions: A Drug Discovery Perspective


  • A deeper dialogue is occurring between infectious and chronic disease disciplines
  • The microbiome opens new therapeutic paradigms for many chronic diseases
  • The host-pathogen interactome offers new ways for treating infectious diseases
  • Using examples from GSK research the translational science of the microbiome and interactome will be discussed

Development of Pathogen-Specific Antimicrobials to Restore Balance to the Human Microbiome


  • Selective antimicrobial peptides remove pathogens and spare the healthy microbiome
  • Clinical data support proof of concept for reengineering the oral microbiome
  • Clinical experience enables product development innovation
  • Advancing to the clinic with targeted antimicrobials for the gut microbiome

Lunch and Networking

Predicting the Microbiome: Improved Preclinical Models for Drug Discovery

A Systems Biology Approach to Measuring Human-Microbiome Interactions


  • How to use computational platforms to elucidate disease causalities
  • Mathematical modelling can be leveraged to understand basic mechanisms in human metabolism
  • What are the key disease type mathematical modelling can look to improve?
  • Can mathematical models be used to design modulation of the gut microbiome to treat diseases?

Using Germ-free Mouse Models to Modulate Liver Disease Development


  • Outlining the key research that validates the influence on the liver by the gut microbiota
  • Human gut-microbiota transplants into germ-free suggests that targeting the gut microbiota could be a new therapeutic approach for liver disease management
  • Gut microbiota transplants to germ-free mice can be used in the context of other diseases

Build Winning Partnerships to Achieve Holistic Microbiome Success

Panel Discussion: What Role Will Academic-Industrial Partnerships Play in Leveraging the Potential Success of Microbiome Therapeutics?


  • How can we combine Academic knowledge with industrial processes to elucidate
  • fundamental mechanisms?
  • Outlining the current global successes with establishing microbiome partnerships
  • In a multi-functional team of experts, where do we place the key responsibilities?
  • How to build a win-win research project in partnership to industrialize microbiome
  • applications?

Afternoon Refreshments and Networking

Seizing the Opportunity: Breakout Roundtables


  1. Food versus Pharma- Where will the Microbiome have the Maximum Success?
  • With successful applications in both nutrition and drug development, which approach will be more successful in short and long term?
  • Regulation
  • Project Management
  • Switching from a medical food mindset to a pharmaceutical mind-set
  • Why is there less money invested in the nutrition route?

Jean-Luc Treillou, CEO, Laboratories Nutrition et Cardiometabolism


  1. Where the Microbiome will Matter for the Pharmaceutical Industry and Why?
  • How to apply a pharmaceutical model to an undefined scientific phenomenon?
  • Changing your research approaches, clinical design and business models to develop a successful pharma-biotech relationship
  • How can big pharma resources be best utilised to accelerate the microbiome R&D?

John Hambor, Director of Research Beyond Borders, Boehringer Ingelheim

Chair’s Closing Remarks

End of Conference Day 1